Allowing state pharmacy boards to oversee pharmacy benefit managers creates a conflict of interest and is outside the scope of the boards' appropriate authority, says Ed Buthusiem, a director at Berkeley Research Group. Pharmacy boards should regulate pharmacists, not competitors, Buthusiem said. "It is a conflict of interest to be regulated by those with whom PBMs contract, those who negotiate their payments. It would open up a hornet's nest," added PCMA President and CEO Mark Merritt. In addition, the Federal Trade Commission says such provisions could ease collusion, raising prescription drug prices.

Related Summaries